NCPC(SH:600812) Shang Hai Zheng Quan Bao·2025-12-29 20:56Core Viewpoint - The company has announced a "Quality Improvement and Efficiency Enhancement Action Plan" aimed at promoting high-quality development and enhancing investment value, particularly for small and medium-sized investors [1][3]. Group 1: Business Focus and Strategy - The company focuses on its core business of pharmaceutical product research, production, and sales, emphasizing quality and human health as its mission [1]. - The company aims to enhance operational quality by improving existing business areas and exploring new growth through innovation and collaboration [2][5]. Group 2: Shareholder Returns - The company has established a three-year shareholder return plan (2023-2025), prioritizing cash profit distribution, with a commitment to distribute at least 30% of the average annual distributable profit over the three years [3][4]. - Cumulative cash dividends over the last three accounting years amounted to 68.63 million yuan, exceeding the planned return requirements [3]. Group 3: Technological Innovation - The company has invested approximately 3.7 billion yuan in R&D since 2022, with an annual average R&D investment increase of 108.78% from 2019 to 2021 [5]. - Significant breakthroughs in technology include the approval of a new drug and multiple product launches, demonstrating the company's commitment to innovation [5][6]. Group 4: Investor Relations Management - The company emphasizes effective communication with investors through various channels, ensuring transparency and timely updates on company developments [7][8]. - Regular performance briefings and investor education activities are conducted to enhance investor understanding and protect their rights [7]. Group 5: Corporate Governance - The company adheres to relevant laws and regulations, continuously improving its governance structure and internal control systems to enhance operational standards [9][10]. - A new committee structure has been established to strengthen decision-making and oversight, ensuring fair treatment of all shareholders [10][11].